Phaseline

Companies › Dimerix Bioscience

Dimerix Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Dec 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DMX-200 (repagermanium)
C-C chemokine receptor type 2 (CCR2) inhibitor
CCR2Phase 3FSGSDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05183646DMX-200 (repagermanium)Phase 3FSGSGenitourinaryDec 2029

Targets

CCR2 (1)

Companies with the same targets

–

Companies built like this

Fertility Center of Las Vegas Zydus Lifesciences Granata Bio Chengdu Qingshan Likang Pharmaceutical Hope Medicine (Nanjing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.